Docetaxel for Advanced Breast Cancer
Author Information
Author(s): I Adachi, T Watanabe, S Takashima, M Narabayashi, N Horikoshi, H Aoyama, T Taguchi
Primary Institution: National Cancer Center Hospital
Hypothesis
The study aims to evaluate the anti-tumor activity, time to progression, and clinical toxicity of docetaxel in patients with advanced or recurrent breast cancer.
Conclusion
Docetaxel shows potent activity against metastatic breast cancer and is considered safe at a dose of 60 mg/m².
Supporting Evidence
- Five patients obtained a complete response and 27 a partial response.
- The overall response rate was 44.4%.
- Leucocytopenia and neutropenia were the major toxicities, occurring in 78.9% and 85.9% of patients respectively.
- The median duration of response was 110 days.
- 31.3% of patients did not experience disease progression during the study.
Takeaway
This study tested a new cancer drug called docetaxel on patients with advanced breast cancer, and it helped many of them feel better.
Methodology
Patients received at least two cycles of docetaxel 60 mg/m² intravenously at 3-4 week intervals, and their responses were evaluated.
Potential Biases
Potential bias due to the study being conducted at multiple hospitals and the involvement of a monitoring committee.
Limitations
The study had a relatively small sample size and was limited to patients with specific eligibility criteria.
Participant Demographics
Patients aged 15-80 years with performance status (PS) of 0-2.
Statistical Information
Confidence Interval
95% CI 32.7-56.6%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website